Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC

This study is comparing two immunotherapy drugs — serplulimab versus nivolumab — both combined with chemotherapy, as pre-surgery treatment (neoadjuvant therapy) for patients with resectable Stage II or IIIA squamous non-small cell lung cancer. The goal is to shrink the tumor before surgery and see which combination works better. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with Stage II or IIIA squamous non-small cell lung cancer confirmed by biopsy - Your cancer is considered removable by surgery - You are in good enough health to undergo lung cancer surgery **You may NOT be eligible if...** - Your cancer has already spread beyond the chest or is Stage IIIB or higher - You have active autoimmune disease requiring treatment - You have had serious prior lung conditions or interstitial lung disease - You are pregnant or breastfeeding - You have previously received immunotherapy for this cancer Talk to your doctor to see if this trial is right for you.